Literature DB >> 32124955

New drugs are not enough‑drug repositioning in oncology: An update.

Romina Gabriela Armando1, Diego Luis Mengual Gómez1, Daniel Eduardo Gomez1.   

Abstract

Drug repositioning refers to the concept of discovering novel clinical benefits of drugs that are already known for use treating other diseases. The advantages of this are that several important drug characteristics are already established (including efficacy, pharmacokinetics, pharmacodynamics and toxicity), making the process of research for a putative drug quicker and less costly. Drug repositioning in oncology has received extensive focus. The present review summarizes the most prominent examples of drug repositioning for the treatment of cancer, taking into consideration their primary use, proposed anticancer mechanisms and current development status.

Entities:  

Year:  2020        PMID: 32124955     DOI: 10.3892/ijo.2020.4966

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  18 in total

Review 1.  Drug repurposing-an emerging strategy in cancer therapeutics.

Authors:  Khadija Shahab Turabi; Ankita Deshmukh; Sayan Paul; Dayanand Swami; Shafina Siddiqui; Urwashi Kumar; Shreelekha Naikar; Shine Devarajan; Soumya Basu; Manash K Paul; Jyotirmoi Aich
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-06-13       Impact factor: 3.195

2.  Improving the odds of success in antitumoral drug development using scoring approaches towards heterocyclic scaffolds.

Authors:  George Nicolae Daniel Ion; Octavian Tudorel Olaru; Georgiana Nitulescu; Iulia Ioana Olaru; Aristidis Tsatsakis; Tatiana I Burykina; Demetrios A Spandidos; George Mihai Nitulescu
Journal:  Oncol Rep       Date:  2020-06-05       Impact factor: 3.906

3.  Metformin induces apoptosis and inhibits migration by activating the AMPK/p53 axis and suppressing PI3K/AKT signaling in human cervical cancer cells.

Authors:  Ya-Hui Chen; Shun-Fa Yang; Chueh-Ko Yang; Horng-Der Tsai; Tze-Ho Chen; Ming-Chih Chou; Yi-Hsuan Hsiao
Journal:  Mol Med Rep       Date:  2020-11-25       Impact factor: 2.952

4.  Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy.

Authors:  Rosalba Florio; Simone Carradori; Serena Veschi; Davide Brocco; Teresa Di Genni; Roberto Cirilli; Adriano Casulli; Alessandro Cama; Laura De Lellis
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-17

5.  Transposon-triggered innate immune response confers cancer resistance to the blind mole rat.

Authors:  Yang Zhao; Ena Oreskovic; Quanwei Zhang; Quan Lu; Abbey Gilman; Yifei S Lin; Junyue He; Zhizhong Zheng; J Yuyang Lu; Jina Lee; Zhonghe Ke; Julia Ablaeva; Matthew J Sweet; Steve Horvath; Zhengdong Zhang; Eviatar Nevo; Andrei Seluanov; Vera Gorbunova
Journal:  Nat Immunol       Date:  2021-09-23       Impact factor: 25.606

Review 6.  Multi-Omics Analysis in Initiation and Progression of Meningiomas: From Pathogenesis to Diagnosis.

Authors:  Jiachen Liu; Congcong Xia; Gaiqing Wang
Journal:  Front Oncol       Date:  2020-08-28       Impact factor: 6.244

7.  A Higher Frequency Administration of the Nontoxic Cycloartane-Type Triterpene Argentatin A Improved Its Anti-Tumor Activity.

Authors:  Zaira Tavarez-Santamaría; Nadia J Jacobo-Herrera; Leticia Rocha-Zavaleta; Alejandro Zentella-Dehesa; Beatriz Del Carmen Couder-García; Mariano Martínez-Vázquez
Journal:  Molecules       Date:  2020-04-14       Impact factor: 4.411

Review 8.  Recycling the Purpose of Old Drugs to Treat Ovarian Cancer.

Authors:  Mariana Nunes; Miguel Henriques Abreu; Carla Bartosch; Sara Ricardo
Journal:  Int J Mol Sci       Date:  2020-10-20       Impact factor: 5.923

Review 9.  Cardiac Glycosides as Autophagy Modulators.

Authors:  Jan Škubník; Vladimíra Svobodová Pavlíčková; Jana Psotová; Silvie Rimpelová
Journal:  Cells       Date:  2021-11-28       Impact factor: 6.600

10.  CCA-1.1, a Novel Curcumin Analog, Exerts Cytotoxic anti- Migratory Activity toward TNBC and HER2-Enriched Breast Cancer Cells.

Authors:  Dhania Novitasari; Riris Istighfari Jenie; Rohmad Yudi Utomo; Jun Ya Kato; Edy Meiyanto
Journal:  Asian Pac J Cancer Prev       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.